Sonoma Pharmaceuticals (SNOA) Invested Capital (2011 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Invested Capital came in at $222000.0 in Q1 2026, up 0.91% year-on-year from $220000.0 in Q1 2025, and up 296.43% quarter-over-quarter from $56000.0 in Q3 2025.
Sonoma Pharmaceuticals (SNOA) Invested Capital (2011 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Invested Capital history runs 16 years deep, the most recent figure standing at $222000.0 for Q1 2026.
- On a quarterly basis, Invested Capital rose 0.91% year-over-year to $222000.0 in Q1 2026; TTM through Mar 2026 was $417000.0, a 17.59% decrease from a year earlier, with the FY2026 full-year figure at $222000.0, up 0.91% from the prior year.
- Invested Capital advanced to $222000.0 in Q1 2026 per SNOA's latest filing, from $56000.0 in the prior quarter.
- Across five years, Invested Capital topped out at $688000.0 in Q1 2022 and bottomed at $44000.0 in Q4 2023.
- The 5-year median for Invested Capital is $221000.0 (2025), against an average of $255000.0.
- Biggest YoY gain for Invested Capital was 15.44% in 2022; the steepest drop was 64.96% in 2022.
- Year by year, Invested Capital stood at $229000.0 in 2022, then slumped by 80.79% to $44000.0 in 2023, then surged by 86.36% to $82000.0 in 2024, then slumped by 31.71% to $56000.0 in 2025, then surged by 296.43% to $222000.0 in 2026.
- Per Business Quant, the three latest SNOA Invested Capital figures stand at $222000.0 (Q1 2026), $56000.0 (Q3 2025), and $139000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 2.61 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 31.13 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 7.15 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.93 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 73.00 Mn |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | 222,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 222,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Jun 30, 2025 | 139,000.00 |
| Mar 31, 2025 | 220,000.00 |
| Sep 30, 2024 | 82,000.00 |
| Jun 30, 2024 | 204,000.00 |
| Mar 31, 2024 | 323,000.00 |
| Dec 31, 2023 | 44,000.00 |
| Sep 30, 2023 | 172,000.00 |
| Jun 30, 2023 | 301,000.00 |
| Mar 31, 2023 | 431,000.00 |
| Sep 30, 2022 | 229,000.00 |
| Jun 30, 2022 | 459,000.00 |
| Mar 31, 2022 | 688,000.00 |
| Dec 31, 2021 | 587,000.00 |
| Sep 30, 2021 | 587,000.00 |
| Jun 30, 2021 | 1.31 Mn |
| Mar 31, 2021 | 596,000.00 |
| Sep 30, 2020 | 49,000.00 |
| Jun 30, 2020 | 265,000.00 |